Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Advaxis Inc (ADXS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 122,248
  • Shares Outstanding, K 41,300
  • Annual Sales, $ 12,030 K
  • Annual Income, $ -93,440 K
  • 36-Month Beta 1.91
  • Price/Sales 10.06
  • Price/Cash Flow N/A
  • Price/Book 2.22
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.31
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/09/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.71 +9.23%
on 12/26/17
3.58 -17.32%
on 12/20/17
-0.04 (-1.33%)
since 12/12/17
3-Month
2.71 +9.23%
on 12/26/17
4.24 -30.19%
on 10/17/17
-1.18 (-28.50%)
since 10/12/17
52-Week
2.71 +9.23%
on 12/26/17
10.06 -70.58%
on 03/06/17
-5.90 (-66.59%)
since 01/12/17

Most Recent Stories

More News
Aratana Therapeutics Granted Conditional License for a Canine Osteosarcoma Therapeutic

Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, today announced the United...

ADXS : 2.96 (+1.02%)
PETX : 5.22 (-1.32%)
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance

Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy Index, a stock index of the top 30 companies developing...

ADXS : 2.96 (+1.02%)
CNCR : 25.70 (+2.47%)
CRIS : 0.74 (+5.00%)
IDRA : 2.49 (+4.18%)
SNDX : 9.19 (-3.26%)
NKTR : 72.00 (+3.03%)
PIRS : 7.46 (+0.95%)
Advaxis to Host Business Update and Fiscal Year End 2017 Financial Results Conference Call on December 21, 2017

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that the Company will...

ADXS : 2.96 (+1.02%)
Quotidian Technical Highlights on Selected Biotech Stocks -- Advaxis, Grifols, Juno Therapeutics, and Lexicon Pharma

In keeping with the commitment to dynamically provide members with timely information WallStEquities.com has issued free tailored Stock Review on ADXS, GRFS, JUNO, and LXRX which is a click away at http://www.wallstequities.com/registration....

ADXS : 2.96 (+1.02%)
LXRX : 10.24 (-0.49%)
GRFS : 24.76 (+0.45%)
JUNO : 48.75 (-2.68%)
Analysis: Positioning to Benefit within Diebold, Liberty TripAdvisor, Paycom Software, First American, Advaxis, and Sanmina -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Diebold, Incorporated (NYSE:DBD),...

ADXS : 2.96 (+1.02%)
DBD : 18.35 (+0.82%)
LTRPB : 12.42 (+21.17%)
FAF : 59.43 (-0.13%)
SANM : 34.35 (+1.03%)
LTRPA : 10.10 (+4.66%)
PAYC : 88.75 (+5.03%)
Advaxis to Present at the Jefferies 2017 London Healthcare Conference

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announces that company...

ADXS : 2.96 (+1.02%)
Advaxis to Receive $4.5 Million through the New Jersey Economic Development Authority NOL Program

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, has received approval for a $4.8...

ADXS : 2.96 (+1.02%)
Richard J Berman Joins 12 ReTech Corporation (OTC: RETC)

12 ReTech Corporation (OTC: RETC) announced today that it had formed an Advisory Board of Directors and Richard J. Berman had joined the Company to serve as its initial Advisory Board Member.

ADXS : 2.96 (+1.02%)
RETC : 0.1622 (+1.38%)
Developments in the Cancer Immunotherapy Market

According to data provided by Grand View Research Inc., the global cancer immunotherapy market is expected to reach USD 118.8 billion by 2025. The market is expected to benefit from introduction of newer...

ADXS : 2.96 (+1.02%)
RGBP : 0.0494 (-3.14%)
CRIS : 0.74 (+5.00%)
ONCS : 1.94 (-3.00%)
INFI : 2.05 (+3.02%)
Biotech Stock Performance Review -- Agenus, Akebia Therapeutics, Acorda Therapeutics, and Advaxis

If you want a Stock Review on AGEN, AKBA, ACOR, or ADXS then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. Today, DailyStockTracker.com features the Biotech...

ADXS : 2.96 (+1.02%)
AGEN : 3.87 (-0.26%)
AKBA : 15.68 (+0.64%)
ACOR : 25.85 (+0.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Advaxis, Inc. is a development stage biotechnology company focused on developing safe and effective cancer vaccines that utilize multiple mechanisms of immunity. The Company is developing a live Listeria vaccine technology under license from the University of Pennsylvania which secretes a protein sequence...

See More

Key Turning Points

2nd Resistance Point 3.07
1st Resistance Point 3.02
Last Price 2.96
1st Support Level 2.91
2nd Support Level 2.85

See More

52-Week High 10.06
Fibonacci 61.8% 7.25
Fibonacci 50% 6.39
Fibonacci 38.2% 5.52
Last Price 2.96
52-Week Low 2.71

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.